By Basant El-Faramawy
Scientists have administered a virus designed by artificial intelligence to a human patient for the first time, aiming to combat antibiotic-resistant infections. California-based startup Radical Numerics said its AI model, Omnii-1, created bacteriophages tailored to the patient's specific bacterial strain.
Experimental treatment and early results
The treatment was given through a special program allowing experimental therapies when conventional options are exhausted. The company reported that lab tests showed the AI-designed virus mixture eliminated the patient's antibiotic-resistant bacteria, but it has not disclosed the patient's diagnosis, outcome, or whether the infection was cleared. The announcement, published on the company's website, has not been peer-reviewed.
How the AI model accelerates phage therapy
Phage therapy already uses naturally occurring viruses to target bacteria, but finding a matching phage can be slow. Radical Numerics says Omnii-1 can redesign viruses in days to better recognize and attack a particular bacterial strain, potentially speeding up treatment development.
Parallel AI virus research
The development follows other AI-driven virus research. In August, researchers at Stanford University and the Arc Institute used AI to design novel viruses that killed E. coli in lab experiments. Of nearly 300 AI-designed viral genomes synthesized, 16 produced functional viruses. Those experiments were conducted in bacteria, not humans.
Biosafety concerns raised
Experts have raised biosafety concerns about AI systems capable of designing new viruses, warning that similar methods could be adapted to create human-infecting pathogens. The Stanford team focused on bacteria-targeting viruses, but scientists call for stronger safeguards as AI-driven biological research advances.
